-
公开(公告)号：US11185543B2
公开(公告)日：2021-11-30
申请号：US16859357
申请日：2020-04-27
申请人： Celgene Corporation
发明人： Matthew D. Alexander , Gerald D. Artman, III , James Carmichael , Brian E. Cathers , Matthew D. Correa , Joshua Hansen , Courtney G. Havens , Timothy S. Kercher , Antonia Lopez-Girona , Xiaoling Lu , Hon-Wah Man , Mark A. Nagy , Joseph R. Piccotti , Daniel W. Pierce , Paula A. Tavares-Greco , Brandon W. Whitefield , Lilly L. Wong , Nanfei Zou
IPC分类号： A61K31/496 , C07D401/04 , A61K31/573 , A61P35/02 , A61K38/05 , A61P35/00 , A61K31/69
摘要： Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
-
公开(公告)号：US20240207255A1
公开(公告)日：2024-06-27
申请号：US18419894
申请日：2024-01-23
申请人： Celgene Corporation
发明人： Matthew D. Alexander , Gerald D. Artman , Gordon L. Bray , James Carmichael , Soraya Carranico , Brian E. Cathers , Matthew D. Correa , Joshua Hansen , Courtney G. Havens , Timothy S. Kercher , Antonia Lopez-Girona , Xiaoling Lu , Hon-Wah Man , Mark A. Nagy , Rama K. Narla , Joseph R. Piccotti , Daniel W. Pierce , Paula A. Tavares-Greco , Brandon W. Whitefield , Lilly L. Wong , Nanfei Zou
IPC分类号： A61K31/496 , A61K31/573 , A61K31/69 , A61K38/05 , A61P35/00 , A61P35/02 , C07D401/04
CPC分类号： A61K31/496 , A61K31/573 , A61K38/05 , A61P35/00 , A61P35/02 , C07D401/04 , A61K31/69 , A61K2300/00
摘要： Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
-
3.发明授权公开(公告)号：US11439637B2
公开(公告)日：2022-09-13
申请号：US16419971
申请日：2019-05-22
申请人： Celgene Corporation
发明人： Daniel W. Pierce , Lilly L. Wong
IPC分类号： A61K31/496 , A61P35/02 , C07K16/28 , A61K45/06
摘要： Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) provided herein, in treating, preventing or managing multiple myeloma.
-
公开(公告)号：US20230341375A1
公开(公告)日：2023-10-26
申请号：US18216405
申请日：2023-06-29
申请人： Celgene Corporation
发明人： Maria Soraya Carrancio Anton , Joshua Hansen , Courtney G. Havens , Antonia Lopez-Girona, SR. , Gang Lu , Daniel W. Pierce , Lilly L. Wong
IPC分类号： G01N33/50 , G01N33/68 , G01N33/574 , A61K31/496 , A61P35/02
CPC分类号： G01N33/5011 , G01N33/6869 , G01N33/57484 , A61K31/496 , G01N33/6866 , A61P35/02 , G01N2800/52 , A61K45/06
摘要： A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
-
公开(公告)号：US20210181184A1
公开(公告)日：2021-06-17
申请号：US17173176
申请日：2021-02-10
申请人： Celgene Corporation
发明人： Maria Soraya Carrancio Anton , Joshua Hansen , Courtney G. Havens , Antonia Lopez-Girona , Gang Lu , Daniel W. Pierce , Lilly L. Wong
IPC分类号： G01N33/50 , G01N33/68 , G01N33/574 , A61K31/496
摘要： A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
-
公开(公告)号：US12090147B2
公开(公告)日：2024-09-17
申请号：US17089359
申请日：2020-11-04
申请人： Celgene Corporation
IPC分类号： A61K31/454 , A61K31/047 , A61K31/4545 , A61K31/573 , A61K31/593 , A61K33/06 , A61K38/20 , A61K39/395 , A61K45/06 , C07D401/04 , C07D401/14
CPC分类号： A61K31/454 , A61K31/047 , A61K31/4545 , A61K31/573 , A61K31/593 , A61K33/06 , A61K38/2006 , A61K39/3955 , A61K45/06 , C07D401/04 , C07D401/14
摘要： Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1β blocker.
-
公开(公告)号：US12029738B2
公开(公告)日：2024-07-09
申请号：US17521432
申请日：2021-11-08
申请人： Celgene Corporation
发明人： Matthew D. Alexander , Gerald D. Artman , Gordon L. Bray , James Carmichael , Soraya Carrancio , Brian E. Cathers , Matthew D. Correa , Joshua Hansen , Courtney G. Havens , Timothy S. Kercher , Antonia Lopez-Girona , Xiaoling Lu , Hon-Wah Man , Mark A. Nagy , Rama K. Narla , Joseph R. Piccotti , Daniel W. Pierce , Paula A. Tavares-Greco , Brandon W. Whitefield , Lilly L. Wong , Nanfei Zou
IPC分类号： A61K31/496 , A61K31/573 , A61K38/05 , A61P35/00 , A61P35/02 , C07D401/04 , A61K31/69
CPC分类号： A61K31/496 , A61K31/573 , A61K38/05 , A61P35/00 , A61P35/02 , C07D401/04 , A61K31/69 , A61K2300/00 , A61K31/496 , A61K2300/00 , A61K31/573 , A61K2300/00 , A61K38/05 , A61K2300/00
摘要： Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
-
8.发明公开公开(公告)号：US20230181575A1
公开(公告)日：2023-06-15
申请号：US17820534
申请日：2022-08-17
申请人： Celgene Corporation
发明人： Daniel W. Pierce , Lilly L. Wong
IPC分类号： A61K31/496 , A61P35/02 , C07K16/28
CPC分类号： A61K31/496 , A61P35/02 , C07K16/2809 , C07K16/2878 , A61K45/06
摘要： Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) provided herein, in treating, preventing or managing multiple myeloma.
-
公开(公告)号：US20210128545A1
公开(公告)日：2021-05-06
申请号：US17089359
申请日：2020-11-04
申请人： Celgene Corporation
IPC分类号： A61K31/454 , A61K31/573 , A61K38/20 , A61K39/395 , A61K33/06 , A61K31/593 , A61K31/047 , A61K45/06
摘要： Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1β blocker.
-
公开(公告)号：US20190282567A1
公开(公告)日：2019-09-19
申请号：US16430189
申请日：2019-06-03
申请人： Celgene Corporation
发明人： Matthew D. Alexander , Gerald D. Artman, III , Gordon L. Bray , James Carmichael , Soraya Carrancio , Brian E. Cathers , Matthew D. Correa , Joshua Hansen , Courtney G. Havens , Timothy S. Kercher , Antonia Lopez-Girona , Xiaoling Lu , Hon-Wah Man , Mark A. Nagy , Rama K. Narla , Joseph R. Piccotti , Daniel W. Pierce , Paula A. Tavares-Greco , Brandon W. Whitefield , Lilly L. Wong , Nanfei Zou
IPC分类号： A61K31/496 , C07D401/04 , A61K31/573 , A61P35/02 , A61K38/05 , A61P35/00
摘要： Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.016 秒)
